Squarepoint
PRLD icon

Squarepoint’s Prelude Therapeutics PRLD Stock Holding History

Squarepoint’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,418
Closed -$126K – 4482
2023
Q4 		$126K Sell
29,418
-59,384
-67% -$181K ﹤0.01% 3710
2023
Q3 		$274K Buy
88,802
+69,675
+364% +$261K ﹤0.01% 3226
2023
Q2 		$86.1K Buy
+19,127
New +$114K ﹤0.01% 3385
2022
Q3 		– Sell
-19,618
Closed -$102K – 3340
2022
Q2 		$102K Sell
19,618
-11,716
-37% -$59.6K ﹤0.01% 2616
2022
Q1 		$216K Sell
31,334
-17,333
-36% -$159K ﹤0.01% 2441
2021
Q4 		$606K Buy
+48,667
New +$792K ﹤0.01% 2019
2021
Q1 		– Sell
-20,726
Closed -$1.48M – 3512
2020
Q4 		$1.48M Sell
20,726
-33,340
-62% -$1.66M 0.01% 1097
2020
Q3 		$1.63M Buy
+54,066
New +$1.53M 0.02% 745

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Squarepoint's PRLD Position: Q1 2024 in Review

Squarepoint sold out of Prelude Therapeutics (PRLD) in Q1 2024, closing a stake of 29,418 shares — an estimated $126K sold.

Squarepoint first reported a position in PRLD in Q3 2020 and held it in 8 quarters. The position peaked at $1.63M in Q3 2020. 58 funds tracked by Wall St. Rank hold PRLD as of Q1 2024.

  • Squarepoint reported no remaining Prelude Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 29,418 Prelude Therapeutics shares in Q1 2024, an estimated $126K.
  • Squarepoint first reported a position in Prelude Therapeutics in Q3 2020 and held it in 8 quarters.
  • Squarepoint's Prelude Therapeutics position peaked at $1.63M in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.